CareDx Company Profile (NASDAQ:CDNA)

Analyst Ratings

Consensus Ratings for CareDx (NASDAQ:CDNA) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $10.00 (111.86% upside)

Analysts' Ratings History for CareDx (NASDAQ:CDNA)
Show:
DateFirmActionRatingPrice TargetActions
6/15/2016Piper Jaffray Cos.Reiterated RatingOverweight$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016MizuhoBoost Price TargetBuy$8.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Janney Montgomery ScottInitiated CoverageBuy -> Buy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2015Craig HallumBoost Price TargetBuy$10.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/28/2015Raymond James Financial Inc.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for CareDx (NASDAQ:CDNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/6/2016Q1($0.31)($0.37)$6.97 million$6.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2016Q415($0.34)($0.40)$7.44 million$6.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q315($0.25)($0.29)$7.34 million$7.15 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.18)($0.27)$7.28 million$7.13 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.18)($0.19)$6.82 million$7.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.13)$0.12$6.60 million$6.65 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/27/2014Q2 14($0.13)$0.13ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CareDx (NASDAQ:CDNA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.32)($0.29)($0.31)
Q2 20162($0.30)($0.21)($0.26)
Q3 20162($0.22)($0.22)($0.22)
Q4 20162($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CareDx (NASDAQ:CDNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CareDx (NASDAQ:CDNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/14/2016Neil GagnonMajor ShareholderBuy93,240$4.02$374,824.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Neil Gagnonmajor shareholderBuy1,431$4.99$7,140.69View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/20/2015Neil GagnonMajor ShareholderBuy1,347$4.92$6,627.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2015Neil Gagnonmajor shareholderBuy6,332$6.10$38,625.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Neil GagnonMajor ShareholderBuy69,383$6.95$482,211.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Neil GagnonMajor ShareholderBuy6,500$5.69$36,985.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Peter MaagCEOBuy2,000$4.84$9,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2015Neil GagnonMajor ShareholderBuy13,051$5.34$69,692.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Neil GagnonMajor ShareholderBuy6,324$6.35$40,157.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2015Neil GagnonMajor ShareholderBuy4,270$6.03$25,748.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Neil GagnonMajor ShareholderBuy4,586$7.20$33,019.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2015Neil GagnonMajor ShareholderBuy121,587$7.10$863,267.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Neil GagnonMajor ShareholderBuy31,991$7.00$223,937.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Neil GagnonMajor ShareholderBuy23,558$7.03$165,612.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Neil GagnonMajor ShareholderBuy3,620$7.05$25,521.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2015Neil GagnonMajor ShareholderBuy15,395$7.04$108,380.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Neil GagnonMajor ShareholderBuy84,720$7.00$593,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2015Neil GagnonMajor ShareholderBuy48,670$7.13$347,017.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Neil GagnonMajor ShareholderBuy16,192$6.66$107,838.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Neil GagnonMajor ShareholderBuy39,109$6.43$251,470.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Neil GagnonMajor ShareholderBuy122,319$7.07$864,795.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2014Ken LudlumCFOBuy7,000$10.00$70,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2014Michael GoldbergDirectorBuy25,000$10.00$250,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2014Perkins Caufield & Bye KleinerMajor ShareholderBuy52,770$10.00$527,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CareDx (NASDAQ:CDNA)
DateHeadline
07/19/16 03:11 PMCAREDX, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and Ex -
07/17/16 07:47 AMCareDx : Appoints Douglas Miller to Its Board of Directors
07/15/16 03:01 PMCareDx Appoints Douglas Miller to Its Board of Directors - [GlobeNewswire] - BRISBANE, Calif., July 15, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions ...
07/13/16 08:33 PMCareDx : Novitas's Proposed Cut In Reimbursement Rate Of Blood Test Threatens Heart Transplant Patient Care In Texas
07/13/16 02:01 PMFirst Coast's Proposed Cut In Reimbursement Rate Of Blood Test Threatens Heart Transplant Patient Care In Florida - [PR Newswire] - TAMPA, Fla., July 13, 2016 /PRNewswire/ -- CareDx, Inc. (CDNA), a molecular diagnostics company, today called for Medicare Administrative Contractor First Coast Service Options, Inc. to reverse its recent proposal to drastically reduce reimbursement for its FDA-cleared diagnostic test AlloMap, which measures gene expression levels to help clinicians determine a heart transplant recipient's risk for organ rejection. Mr. Maag spoke today at a telephonic press conference along with Florida heart transplant recipient Kenneth Mitchell and leading Florida cardiologist Debbie Hoffman, who talked of the importance of AlloMap and called on First Coast to reverse its proposal.
07/13/16 01:56 PMNovitas's Proposed Cut In Reimbursement Rate Of Blood Test Threatens Heart Transplant Patient Care In Texas - [PR Newswire] - DALLAS, July 13, 2016 /PRNewswire/ -- CareDx, Inc. (CDNA), a molecular diagnostics company, today called for Medicare Administrative Contractor Novitas Solutions, Inc. to reverse its recent proposal to drastically reduce reimbursement for its FDA-cleared diagnostic test AlloMap, which measures gene expression levels to help clinicians determine a heart transplant recipient's risk for organ rejection. Dr. Maag spoke today at a telephonic press conference along with Texas heart transplant recipient Zeke Arguello and leading Texas cardiologist Dr. Pradeep Maamen, who talked of the importance of AlloMap and called on Novitas to reverse its proposal.
06/29/16 08:11 PMCareDx : Responds to CMS Proposal
06/29/16 12:21 PMCareDx Responds to CMS Proposal - [at noodls] - a02c41b4-bbdb-484b-9c8e-bbdd855ad5a8.pdf CAREDX RESPONDS TO CMS PROPOSAL TO CUT ALLOMAP PRICING BY 74% CareDx engages with local Medicare Contractors to prove that CMS proposal is factually baseless BRISBANE, ...
06/29/16 07:00 AMCareDx Responds to CMS Proposal to Cut AlloMap Pricing by 74% - [PR Newswire] - BRISBANE, Calif., June 29, 2016 /PRNewswire/ -- CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, is challenging the recent proposal by Center of Medicare and Medicaid Services (CMS) as being harmful for heart transplant patients. AlloMap® is a non-invasive blood test for heart transplant recipients to determine the risk of acute cellular rejection. AlloMap is the only alternative to an Endomyocardial Biopsy (EMB), which is more invasive, riskier and costlier for taxpayers. The current Medicare rate paid for AlloMap is $2,821 per testing service, which is in line with many advanced diagnostic tests.
06/21/16 02:09 PMCAREDX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 03:48 PMCAREDX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, -
06/15/16 03:00 PMCareDx Announces New Employment Inducement Grants - [GlobeNewswire] - BRISBANE, Calif., June 15, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions ...
06/15/16 07:54 AMMizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition
06/14/16 07:25 AMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.74%
06/13/16 02:35 PMAlloSure™ Shows Promise to Detect Rejection in Transplant Patients with a Simple Blood Test
06/06/16 07:00 AMCareDx to Host Call to Provide First Analysis of Data from DART Study - [GlobeNewswire] - BRISBANE, Calif., June 06, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions ...
06/01/16 11:42 AMCareDx (CDNA), QIAGEN Enter HLA Lab Collaboration - Get your Free Trial here. CareDx, Inc. (Nasdaq: CDNA) announced it has signed a memorandum of understanding to collaborate with QIAGEN, the leading provider of Sample to Insight solutions for the life sciences and diagnostics industry. Under the terms of ...
06/01/16 11:15 AMCareDx, Inc. :CDNA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/31/16 07:00 AMCareDx to Present at 2016 Jefferies Healthcare Conference - [GlobeNewswire] - BRISBANE, Calif., May 31, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions ...
05/31/16 07:00 AMCareDx and QIAGEN Enter Into Commercial Collaboration to Enhance HLA Lab Experience Using QIAxcel Instrumentation and CareDx HLA Typing Technology - [GlobeNewswire] - BRISBANE, Calif., May 31, 2016-- CareDx, Inc., a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions ...
05/27/16 03:12 PMCAREDX, INC. Files SEC form 8-K/A, Financial Statements and Exhibits -
05/27/16 03:05 PMCareDx Announces Completion of Enrollment in Multicenter Kidney Transplant Study to Validate Cell-Free DNA Technology - [GlobeNewswire] - BRISBANE, Calif., May 27, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions ...
05/27/16 03:27 AMThe HeartBrothers Foundation Presented With Support from CareDx to expand Heart Transplant Education and Patient Support - [at noodls] - Media Contacts: CareDx: Molly Martell, 415-728-6307, [email protected] HeartBrothers: Pat Sullivan, 508-579-5878, [email protected] The HeartBrothers Foundation ...
05/25/16 01:06 PMDIAXONHIT and the University Hospitals of Strasbourg launch the Central European Laboratory Dedicated to AlloMap® Testing - [at noodls] - b5649c95-93e4-4826-a2e9-bd770700e3a1.pdf PRESS RELEASE DIAXONHIT - Heart transplant monitoring DIAXONHIT and the University Hospitals of Strasbourg launch the Central European Laboratory dedicated to AlloMap® ...
05/21/16 06:03 AMCareDx Initiates Compulsory Acquisition Proceedings and Allenex Files for De-Listing - [at noodls] - ee0b533e-5849-497d-a349-b2e48fd85c9b.pdf Press release May 20 2016 CAREDX INITIATES COMPULSORY ACQUISITION PROCEEDINGS AND ALLENEX FILES FOR DE-LISTING CareDx, Inc ("CareDx") announced on 8 April ...
05/17/16 04:14 PMCAREDX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
05/16/16 05:17 PMCAREDX, INC. Files SEC form 10-Q, Quarterly Report -
05/09/16 06:34 AMEdited Transcript of CDNA earnings conference call or presentation 6-May-16 12:30pm GMT -
05/06/16 07:04 AMCAREDX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/06/16 06:50 AMCareDx reports 1Q loss -
05/06/16 06:30 AMCareDx, Inc. Reports First Quarter 2016 Financial Results - [GlobeNewswire] - BRISBANE, Calif., May 06, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions ...
05/06/16 06:07 AMQ1 2016 CareDx Inc Earnings Release - Before Market Open -
04/28/16 05:54 PMCareDx to Present Clinical Abstracts Containing New Data at the 2016 ISHLT On AlloMap® & AlloSure™ in Heart Transplant Patients - [at noodls] - 7da3cd49-fcaf-4303-bf55-1e0432841a1d.pdf NEWS RELEASE CareDx to Present Clinical Abstracts Containing New Data at the 2016 ISHLT On AlloMap® & AlloSure™ in heart transplant patients Brisbane, CA -April ...
04/27/16 06:31 AMCareDx to Announce First Quarter 2016 Financial Results and Host Conference Call on May 6, 2016 - [at noodls] - 96bdb551-88e4-4ee5-a32c-59cae2cb1859.pdf BRISBANE, CA, April 26, 2016: CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically ...
03/10/16 06:30 AMCareDx to Announce Fourth Quarter and 2015 Year-End Financial Results on March 24 and Will Present at the 28th Annual Roth Conference on March 16 - [GlobeNewswire] - BRISBANE, Calif., March 10, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance ...
03/08/16 06:30 AMCareDx Receives Positive Coverage Decision for AlloMap® From TRICARE® Covering Over 9 Million Lives of U.S. Military Members and Their Families - [GlobeNewswire] - BRISBANE, Calif., March 08, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance ...
03/07/16 01:08 AMCareDX, Inc.: CareDx Announces Offer Document for its Recommended Offer to All Shareholders in Allenex - [Business Wire] - Regulatory News:
02/29/16 01:26 AMCareDx Announces Revised Timeline to Its Offer to Acquire Allenex - [GlobeNewswire] - BRISBANE, Calif., Feb. 29, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance ...
02/29/16 01:15 AMCareDX, Inc.: CareDx Announces a Revised Timeline for its Recommended Offer to All Shareholders in Allenex - [Business Wire] - Regulatory News:
02/10/16 09:24 AMJanney Initiates CareDx With Buy Rating, $12 Target -
02/09/16 03:25 AM4:25 am CareDx revises agreement to purchase 78% of outstanding shares of Allenex AB; plans to tender remaining shares in Q1 -
02/09/16 02:01 AMCareDx Announces Revised Agreement to Purchase 78 Percent of the Outstanding Shares of Allenex AB and Plans to Launch Tender for Remaining Shares in First Quarter 2016 - [GlobeNewswire] - BRISBANE, Calif., Feb. 09, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance ...
02/09/16 01:38 AMCareDX, Inc.: CareDx Announces Revised Terms in its Recommended Offer to All Shareholders in Allenex - [Business Wire] - Regulatory News:
02/02/16 03:37 PMCareDx to Participate in Upcoming Healthcare Conferences in February 2016: Leerink, BIO CEO & BTIG - [GlobeNewswire] - BRISBANE, Calif., Feb. 02, 2016-- CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance ...
12/22/15 02:49 PMCAREDX, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Secu -
12/18/15 08:54 AMCareDx, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/16/15 05:45 PMCareDx Announces Agreement to Purchase 78 Percent of the Outstanding Shares of Allenex AB and Plans to Launch Tender for Remaining Shares in First Quarter 2016 - [at noodls] - 24c1d67e-b27d-4a77-81ce-304454fd34e4.pdf Combination Creates an International Transplantation Diagnostics Company with Expanded Distribution and Growth Potential BRISBANE, CA, December 16, 2015: CareDx, ...
12/16/15 06:35 AMCAREDX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
12/08/15 12:18 PMCAREDX, INC. Financials -
12/03/15 12:36 PMCMS Revises Its Pricing Determination for AlloMap® - [at noodls] - 1919d044-f720-40ca-b3cc-346fb9be70fa.pdf Reimbursement for Heart Transplant Surveillance Testing to Remain At Previous Level Decision Is Victory for Transplant Community BRISBANE, Calif., November 17, ...

Social

About CareDx

CareDx logoCareDx, Inc., formerly XDx, Inc. is a commercial-stage company, which develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test or AlloMap, is a non-invasive blood-based test used to monitor heart transplant recipients for acute cellular rejection. AlloMap uses gene expression technology for the identification of heart transplant recipients. AlloMap provides a single integer score ranging from 0 to 40 and determines the probability of moderate to severe acute cellular rejection. As of December 31, 2014, the Company performed more than 66,000 commercial AlloMap tests in total. The Company is also engaged in the new product development in other areas of transplant surveillance, such as the use of cell-free donor de-oxy ribonucleic acid (cfDNA) technology as a biomarker for rejection.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Research Services
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CDNA
  • CUSIP:
Key Metrics:
  • Previous Close: $4.72
  • 50 Day Moving Average: $4.87
  • 200 Day Moving Average: $4.86
  • P/E Ratio: N/A
  • P/E Growth: -0.23
  • Market Cap: $65.89M
  • Beta: 0.84
  • Current Year EPS Consensus Estimate: $-1.01 EPS
  • Next Year EPS Consensus Estimate: $-0.56 EPS
Additional Links:
CareDx (NASDAQ:CDNA) Chart for Sunday, July, 24, 2016